Cobblestone Capital Advisors’s Beam Therapeutics BEAM Stock Holding History

Cobblestone Capital Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,990	Closed	-$229K	–	253
2022 Q1	$229K	Hold	3,990	–	–	0.02%	238
2021 Q4	$318K	Hold	3,990	–	–	0.02%	213
2021 Q3	$347K	Hold	3,990	–	–	0.02%	193
2021 Q2	$514K	Hold	3,990	–	–	0.03%	171
2021 Q1	$319K	Hold	3,990	–	–	0.02%	208
2020 Q4	$326K	Buy	+3,990	New	+$196K	0.03%	196

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cobblestone Capital Advisors's BEAM Position: Q2 2022 in Review

Cobblestone Capital Advisors sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 3,990 shares — an estimated $229K sold.

Cobblestone Capital Advisors first reported a position in BEAM in Q4 2020 and held it in 6 quarters. The position peaked at $514K in Q2 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

Cobblestone Capital Advisors reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
Cobblestone Capital Advisors sold 3,990 Beam Therapeutics shares in Q2 2022, an estimated $229K.
Cobblestone Capital Advisors first reported a position in Beam Therapeutics in Q4 2020 and held it in 6 quarters.
Cobblestone Capital Advisors's Beam Therapeutics position peaked at $514K in Q2 2021.
205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Cobblestone Capital Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.